What’s the current market cap for Bristol-Myers Squibb stock?

Bristol-Myers Squibb (BMY) has a market cap of $112B as of June 02, 2026.

What is the P/E ratio for Bristol-Myers Squibb stock?

The price to earnings (P/E) ratio for Bristol-Myers Squibb (BMY) stock is 15.39 as of June 02, 2026.

Does Bristol-Myers Squibb stock pay dividends?

Yes, the Bristol-Myers Squibb (BMY) stock pays dividends to shareholders. As of June 02, 2026, the dividend rate is $2.5 and the yield is 4.59%. Bristol-Myers Squibb has a payout ratio of 69.69% on a trailing twelve-month basis.

When is the next Bristol-Myers Squibb dividend payment date?

The next Bristol-Myers Squibb (BMY) dividend payment date is unconfirmed.

What is the beta indicator for Bristol-Myers Squibb?

Bristol-Myers Squibb (BMY) has a beta rating of 0.26. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Bristol-Myers Squibb stock | $BMY Share Price

13:30

15:10

16:45

18:25

20:00

About Bristol-Myers Squibb

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Ticker

$BMY

Sector

Health

Primary listing

NYSE

Employees

32,500

Headquarters

Princeton, United States

Website

www.bms.com

BMY Metrics

BasicAdvanced

$112bn

15.39

$3.57

0.26

$2.50

4.59%

What the Analysts think about BMY

Analyst ratings (Buy, Hold, Sell) for Bristol-Myers Squibb stock.

Bulls say / Bears say

First-quarter profit exceeded expectations, led by 12% growth in the growth portfolio to $6.23 billion. The company reaffirmed its 2026 revenue target of $46.0–47.5 billion and gave adjusted EPS guidance of $6.05–6.35, now trending toward the upper end (Reuters)

The FDA accepted the New Drug Application for iberdomide in combination with daratumumab and dexamethasone, granting Breakthrough Therapy designation and Priority Review, with a PDUFA date of August 17, 2026, strengthening Bristol Myers Squibb’s immuno-oncology pipeline (Reuters)

Bristol Myers Squibb entered a collaboration worth up to $850 million with Janux Therapeutics to develop a novel cancer drug, advancing its capabilities in precision oncology research and development (Reuters)

Revlimid revenues dropped 63% year-over-year to $349 million in Q1 2026 after unrestricted generic competition began in January 2026 (Reuters)

In December 2025, a U.S. judge declined to dismiss a $6.7 billion lawsuit that alleges Bristol Myers Squibb delayed Celgene drug approvals, creating significant shareholder litigation risk (Reuters)

Dependence on key pivotal readouts in the second half of 2026 raises execution risk, as setbacks in next-generation cancer drug approvals could threaten growth projections (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 1 Jun 2026.

BMY Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

BMY Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BMY

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Revlimid revenues dropped 63% year-over-year to $349 million in Q1 2026 after unrestricted generic competition began in January 2026 (Reuters)

In December 2025, a U.S. judge declined to dismiss a $6.7 billion lawsuit that alleges Bristol Myers Squibb delayed Celgene drug approvals, creating significant shareholder litigation risk (Reuters)

Dependence on key pivotal readouts in the second half of 2026 raises execution risk, as setbacks in next-generation cancer drug approvals could threaten growth projections (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 1 Jun 2026.